Oyster Point Pharma Inc

Oyster Point Pharma — Technical Presentation (May 2020)

33 slides from Oyster Point Pharma's technical presentation, May 11, 2020

  1. Slide 1: ONSET-2 Phase 3 Study Top-line Results

    ONSET-2 Phase 3 Study Top-line Results May 11, 2020 NASDAQ: OYST

  2. Slide 2: Disclaimers and Forward-Looking Statements

    Disclaimers and Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the “Company,” “we” or “our”) reg

  3. Slide 3: Conference Call Speakers

    Conference Call Speakers Jeffrey Nau, PhD, MMS President and Chief Executive Officer Daniel Lochner, MBA Chief Financial Officer John Snisarenko, MBA Chief Commercial Officer ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 3

  4. Slide 4: OC-01 Nasal Spray Clinical Development Program: ONSET-2 Endpoints Achieved

    OC-01 Nasal Spray Clinical Development Program • Statistically significant improvement in percentage of subjects gaining > 10mm on Schirmer’s Score (primary endpoint) in both doses tested (0.6 mg/ml and 1.2 mg/ml) as compared to control (p<0.0001). Consistent outcome as ONSET-1. • Statistically sign

  5. Slide 5: ONSET-2 Phase 3 Study Design

    ONSET-2 Phase 3 Study Design Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of OC- 01 Nasal Spray on the Signs and Symptoms of Dry Eye Disease 1.2 mg/ml n=246 OC-01 Primary (signs) Endpoint: Nasal Spray • Categorical Schirmer’s Score at Week 4 (

  6. Slide 6: ONSET-2 Phase 3 Study Design Elements

    ONSET-2 Phase 3 Study Design Important Study Design Elements: • No placebo run-in period utilized as part of the study design • Broad dry eye patient eligibility criteria • Subjects could enter with an Eye Dryness Score from 0-100 • Main criteria for entry is Schirmer’s Score <10 • National Eye Inst

  7. Slide 7: Demographics and Baseline Characteristics

    Demographics[1] and Baseline Characteristics[2] OC-01 OC-01 Control Total 0.6 mg / mL 1.2 mg / mL (n=252) (n=758) (n=260) (n=246) Mean Age at Randomization (years) 58.4 59.6 58.4 58.8 Age Range (min, max) 23, 95 22, 91 22, 91 22, 95 Sex Male 51 (20.2) 66 (25.4) 65 (26.4) 182 (24.0) Female 201 (79.8)

  8. Slide 8: Statistically Significant Improvement in Signs

    Statistically Significant Improvement in Signs % Subjects with ≥10mm Change in Schirmer’s Score at Week 4 vs. Baseline Primary Endpoint p<0.0001 p<0.0001 47% 44% 26% Schirmer’s Score Schirmer’s % mm % ≥10within Subjects change n=213 n=218 n=205 Control 0.6 mg/ml 1.2 mg/ml ITT-population (excluding s

  9. Slide 9: Statistically Significant Improvement in Signs

    Statistically Significant Improvement in Signs % Subjects with ≥10mm Change in Schirmer’s Score at Week 4 vs. Baseline Primary Endpoint *p<0.001 *p=0.001 p<0.0001 p<0.0001 60% 60% 54% 50% 48% 50% 47% 44% 40% 40% 30% 30% 26% 20% 20% 14% 10% 10% % % Subjects with≥ Change 10mm in STS % % Subjects with≥

  10. Slide 10: Statistically Significant Improvement in Signs: Schirmer's Score

    Statistically Significant Improvement in Signs Mean Change in Schirmer’s Score at Week 4 vs. Baseline Secondary Sign Endpoint p<0.0001 p<0.0001 11.0 11.2 5.9 Mean Change in Schirmer’sin Change Mean Score* (mm) n=213 n=218 n=205 Control 0.6 mg/ml 1.2 mg/ml ITT-population (excluding sites 48 and 51),

  11. Slide 11: Statistically Significant Improvement in Signs: Schirmer's Score

    Statistically Significant Improvement in Signs Mean Change in Schirmer’s Score at Week 4 vs. Baseline p<0.001 p=0.001 p<0.0001 p<0.0001 12 11.4 12 11.1 11.0 11.2 10 10 8 8 5.9 6 6 3.7 4 4 2 2 Mean Mean Change Score* in Schirmer’s (mm) Mean Mean Change Score* in Schirmer’s (mm) 0 0 n=43 n=46 n=40 n=2

  12. Slide 12: Statistically Significant Improvement in Symptoms: Eye Dryness Score Week 4

    Statistically Significant Improvement in Symptoms[1] Mean Change in Eye Dryness Score at Week 4 vs. Baseline Secondary Symptom Endpoint n=241 n=248 n=233 -15.8 -19.7 p=0.07 Mean Change in Change EDS Mean Score (mm)* P<0.001 P=0.001 -22.5 p=0.002 Control 0.6 mg/ml 1.2 mg/ml ITT-population, Least Squa

  13. Slide 13: Statistically Significant Improvement in Symptoms: Eye Dryness Score

    Statistically Significant Improvement in Symptoms Mean Change in Eye Dryness Score at Week 4 vs. Baseline N=43 N=46 N=40 N=241 N=248 N=233 0 0 -5 -5 -5.6 -10 -10 -15 -15 -15.4 -15.8 p=0.13 -20 -19.0 -20 -19.7 Mean Change in EDS Score (mm)* Score EDS in Change Mean Mean Change in EDS Score (mm)* Scor

  14. Slide 14: Statistically Significant Improvement in Symptoms: Eye Dryness Score Week 2

    Statistically Significant Improvement in Symptoms Mean Change in Eye Dryness Score at Week 2 vs. Baseline Secondary Symptom Endpoint n=248 n=251 n=232 -12.8 -16.5 *p<0.05 -17.9 Mean Change in Change EDS Mean Score (mm)* P<0.001 *p=0.009 Control 0.6 mg/ml 1.2 mg/ml ITT-population, Least Square (LS) m

  15. Slide 15: Improvement in Symptoms: Eye Dryness Score Week 1

    Improvement in Symptoms Mean Change in Eye Dryness Score at Week 1 vs. Baseline Secondary Symptom Endpoint n=248 n=254 n=239 -13.3 Mean Change in EDS Score* -15.7 P<0.001 -15.4 p=0.19 p=0.25 Control 0.6 mg/ml 1.2 mg/ml ITT-population, Least Square (LS) means were derived from ANCOVA model with treat

  16. Slide 16: Statistically Significant Improvement in Symptoms: Secondary Symptom Endpoints

    Statistically Significant Improvement in Symptoms Mean Change in Eye Dryness Score Secondary Symptom Endpoints Week 1 Week 2 Week 4 n=248 n=254 n=239 n=248 n=251 n=232 n=241 n=248 n=233 -13.3 -12.8 -15.7 -15.4 -15.8 -16.5 -17.9 *p<0.05 *p=0.009 -19.7 P<0.001 Mean Change in Change EDS Mean Score (mm)

  17. Slide 17: Improvement in Symptoms: Eye Dryness Score in Controlled Adverse Environment

    Improvement in Symptoms Mean Change in Eye Dryness Score at Week 4 vs. Baseline in Controlled Adverse Environment Secondary Symptom Endpoint n=169 n=187 n=171 -7.4 -9.0 -10.3 p=0.50 Mean Change in Change EDS Mean Score (mm)* P<0.001p=0.20 P=0.001 Control 0.6 mg/ml 1.2 mg/ml ITT-population (excluding

  18. Slide 18: Improvement in Symptoms: Pre-CAE Eye Dryness Score

    Improvement in Symptoms Pre-CAE Mean Change in Eye Dryness Score- Pre-CAE n=212 n=215 n=197 -14.7 -16.9 p=0.31 -19.3 p=0.04 Mean Change in Change EDS Mean Score (mm)* P<0.001 P=0.001 Control 0.6 mg/ml 1.2 mg/ml ITT-population (excluding sites 45 and 48), Least Square (LS) means were derived from ANC

  19. Slide 19: OC-01 Shows Benefit in CAE vs. Control

    OC-01 Shows Benefit in CAE vs. Control Mean Eye Dryness Score in Controlled Adverse Environment Mean EDS at 2 Hours 60 Control Control 59 0.6 mg/ml 56 55 0.6 mg/ml 1.2 mg/ml 52 1.2 mg/ml 50 45 40 Mean EDS at Time 0 Control 35 35 0.6 mg/ml 35 1.2 mg/ml 37 Mean Change in Change EDS Mean Score (mm)* 30

  20. Slide 20: Benefit Favoring OC-01 in ICSS-0.6 mg/ml

    Benefit Favoring OC-01 in ICSS-0.6 mg/ml Mean Change in Inferior Corneal Staining Score (ICSS) at Week 4 vs. Baseline Secondary Sign Endpoint [2} Lease Squares Mean [3] ANCOVA p-value is calculated using a model with treatment, site, baseline corresponding location corneal staining score, baseline S

  21. Slide 21: Benefit Favoring OC-01 in ICSS-1.2 mg/ml

    Benefit Favoring OC-01 in ICSS-1.2 mg/ml Mean Change in Inferior Corneal Staining Score (ICSS) at Week 4 vs. Baseline Secondary Sign Endpoint [2} Lease Squares Mean [3] ANCOVA p-value is calculated using a model with treatment, site, baseline corresponding location corneal staining score, baseline S

  22. Slide 22: Top-Line Data Summary (1.2 mg/ml dose)

    Top-Line Data Summary (1.2 mg/ml dose) Primary Endpoint % Subjects with ≥10mm Change in Schirmer’s Score Week 4 vs. Baseline p<0.0001 Secondary Endpoints Mean Change in Eye Dryness Score at Week 4 vs. Baseline in p>0.05 Controlled Adverse Environment [1] Mean Change in Eye Dryness Score at Week 4 vs

  23. Slide 23: Efficacy Data Summary - 1.2 mg/ml Dose Group

    Efficacy Data Summary- 1.2 mg/ml Dose Group Sole Primary Endpoint Secondary Symptom Endpoints Week 4 Week 1 Week 2 Week 4 n=248 n=239 n=248 n=232 n=241 n=233 0.0 60% p<0.0001 50% 47% -5.0 40% -10.0 30% 26% -12.8 -13.3 -15.0 20% -15.4 -15.8 P=0.25 -17.9 Mean change in EDS Score (mm) change inScore Me

  24. Slide 24: Summary of Treatment-Emergent Adverse Events

    Summary of Treatment-Emergent Adverse Events Control 0.6 mg/mL 1.2 mg/mL Total (n=251) (n=260) (n=245) (n=756) n (%) n (%) n (%) n (%) Subjects with any Treatment Emergent Adverse Events (TEAE) 135 (53.8) 252 (96.9) 241 (98.4) 628 (83.1) Subjects with any Treatment-Related Treatment Emergent Serious

  25. Slide 25: Adverse Event Profile

    Adverse Event Profile Treatment-Emergent Adverse Events in >5% of Subjects Potentially Related to OC-01 OC-01 OC-01 Control Total 0.6 mg / mL 1.2 mg / mL (n=251) (n=756) (n=260) (n=245) Sneeze after any installation 73 (29.1) 247 (95.0) 237 (96.7) 557 (73.7) Cough after any instillation 5 (2.0) 49 (

  26. Slide 26: Nasal Spray Administration Diary - Sneeze

    Nasal Spray Administration Diary - Sneeze Placebo 0.6 mg / mL 1.2 mg / mL (n=251) (n=260) (n=245) % % % Sneeze categorized as Mild (% of admin.) 95.7 99.6 99.2 Administrations That Caused Sneeze (% of admin.) 1.5 52.2 52.0 Average Number of Sneeze per Administration (% of admin.) 0-2 Sneezes 99.7 79

  27. Slide 27: OC-01 Nasal Spray Clinical Development Program

    OC-01 Nasal Spray Clinical Development Program 1 PHASE 1 PHASE 2b PHASE 2 PHASE 3 28-Day Long-term 84 Day 28-Day PK Study Safety & Efficacy Safety & Efficacy Efficacy & Safety Complete Complete Complete Complete * Planning OC-01 label expansion for contact lens intolerance and ocular surface prepara

  28. Slide 28: Loss of Tear Film Leads to Progression of Dry Eye Disease

    Loss of Tear Film Leads to Progression of Dry Eye Disease Healthy Ocular Surface Loss of Tear Film Homeostasis Cycle of Dry Eye Disease Leads to Inflammation Tear Film Homeostasis Fundamental Characteristic of DED and Cell Damage Tear Deficiency & Instability Increased Evaporation Inflammation Irrit

  29. Slide 29: There is No Substitute for Natural Tear Film

    There is No Substitute for Natural Tear Film A healthy tear film lubricates and protects the eyes from injury and infection, washes away foreign particles, and contributes refractive power for clear vision Growth factors, such as nerve growth factor (NGF) and epidermal growth factor (EGF), found in

  30. Slide 30: Significant Unmet Need in the Treatment of Dry Eye Disease

    Significant Unmet Need in the Treatment of Dry Eye Disease Affects 34 MILLION ADULTS Limitations of current treatments: of all ages in the U.S. alone1 and >340 million worldwide2 • Mechanisms of action only address ~16 MILLION inflammation have been diagnosed, but < 2 million are • Slow onset of act

  31. Slide 31: Commercialization of OC-01 Nasal Spray

    Commercialization of OC-01 Nasal Spray If approved, planning 1st launch in the US in Q4 2021. Key commercialization strategies include: Specialty sales Extensive education and Enable patient force marketing campaigns access to OC-01 Competitively sized specialty Broad ECP education and Strategic con

  32. Slide 32: OC-01 Nasal Spray Profile

    OC-01 Nasal Spray Profile: Preservative-free nasal spray with 50 uL spray delivered twice daily to each nostril Novel mechanism of action to restore tear film homeostasis with natural tear production Rapid onset of action observed in clinical trials to significantly improve signs and symptoms Improv

  33. Slide 33: & ONSET

    N & ONSET 2 OYSTER aS OPraint _ NASDAQ: OYST

Oyster Point Pharma — Technical Presentation (May 2020) on 6ix